<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05107492</url>
  </required_header>
  <id_info>
    <org_study_id>B7541013</org_study_id>
    <nct_id>NCT05107492</nct_id>
  </id_info>
  <brief_title>Evaluation of the Pharmacokinetics, Safety and Tolerability of Single Dose of PF-06480605 in Chinese Healthy Participants</brief_title>
  <official_title>A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY FOLLOWING SINGLE SUBCUTANEOUS DOSE OF PF-06480605 IN CHINESE HEALTHY PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, single-center, randomized, double-blind, third-party open (ie, participant&#xD;
      blind, investigator blind and sponsor open), placebo controlled study to investigate PK,&#xD;
      safety, tolerability, immunogenicity, and PD of PF 06480605 following a single subcutaneous&#xD;
      dose of PF-06480605 450 mg and 150 mg (if needed) in Chinese healthy adult participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 19, 2021</start_date>
  <completion_date type="Anticipated">July 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 23, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1 to Day 114</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Day 1 to Day 114</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to End of Dosing Interval (AUC 14 days))</measure>
    <time_frame>Day 1 to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)</measure>
    <time_frame>Day 1 to Day 114</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>Day 1 to Day 114</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Day 1 to Day 114</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with abnormal vital signs</measure>
    <time_frame>Day 1 to Day 114</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with abnormal 12 lead electrocardiograms</measure>
    <time_frame>Day 1 to Day 114</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with abnormal physical examination findings</measure>
    <time_frame>Day 1 to Day 114</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with abnormal clinical safety laboratory measurements</measure>
    <time_frame>Day 1 to Day 114</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>Day 1 to Day 114</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax(dn)</measure>
    <time_frame>Day 1 to Day 114</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf(dn)</measure>
    <time_frame>Day 1 to Day 114</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>Day 1 to Day 114</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F)</measure>
    <time_frame>Day 1 to Day 114</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of the development of ADA and NAb.</measure>
    <time_frame>Day 1 to Day 114</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total sTL1A protein concentration in serum.</measure>
    <time_frame>Day 1 to Day 114</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 participants will be randomly assigned at an allocation ratio of 3:1 to the active treatment 450mg and placebo arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 participants will be randomly assigned at an allocation ratio of 3:1 to the active treatment 150mg and placebo arms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>450mg</intervention_name>
    <description>following a single subcutaneous dose of PF-06480605 450 mg</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>150mg</intervention_name>
    <description>following a single subcutaneous dose of PF-06480605 150 mg</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>following a single subcutaneous dose of placebo</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female participants must be 18 to 45 years of age, inclusive, at the time of&#xD;
             signing the ICD.&#xD;
&#xD;
          -  Male and female Chinese participants who are overtly healthy as determined by medical&#xD;
             evaluation including medical history, physical examination, laboratory tests, vital&#xD;
             sign and 12-lead ECG&#xD;
&#xD;
          -  BMI of 19 to 27 kg/m2; and a total body weight &gt;50 kg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or&#xD;
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,&#xD;
             seasonal allergies at the time of dosing).&#xD;
&#xD;
          -  History of HIV infection, hepatitis B, hepatitis C or syphilis; positive testing for&#xD;
             HIV, hepatitis B, HCVAb or serological reaction of syphilis.&#xD;
&#xD;
          -  History of allergic or anaphylactic reaction to a therapeutic drug.&#xD;
&#xD;
          -  History of recent active infections within 28 days prior to the screening visit.&#xD;
&#xD;
          -  Participants with a fever within 48 hours prior to dosing.&#xD;
&#xD;
          -  History of TB or active or latent or inadequately treated infection.&#xD;
&#xD;
          -  Recent exposure to live vaccines within 28 days of the screening visit.&#xD;
&#xD;
          -  A positive pregnancy test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7541013</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IBD</keyword>
  <keyword>PK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

